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Endocrine disturbances of calcium metabolism in uremia: Renal causes
and systemic consequences. The genesis of the hormonal disturbances in
calcium metabolism of renal failure is complex, but can be understood
basically as the consequence of the deranged endocrine function of the
kidney, that is, failing biosynthesis of the renal secosterol hormone 1,25
0H2D3. It is of interest to note how our concepts concerning the genesis
of these disturbances, and the role of 1,25 0H2D3 therein, have changed
with time. We illustrate this using three examples: (i) the signals activating
the parathyroid gland in early renal failure; (ii) the genesis of parathyroid
hyperplasia; and (iii) the actions of 1,25 0H7D5 in renal failure unrelated
to calcium control.
The work of the late Homer W. Smith was devoted to the
exploration of the function of the kidney. If we go back in time,
the ancient wise ones were of the opinion that "the organs of the
body were created to perform 10 functions, among which it is the
function of the kidney to furnish the human being with thought"
(Leviticus Rabba III, Talmud Berochoth 61b). This view, although
extremely flattering to the nephrologist, is unfortunately not
entirely correct. It serves to illustrate, however, that the concepts
on the kidney's function have changed with time. One of the more
fascinating recent developments is the recognition that, apart
from its long-established exocrine function, the kidney has impor-
tant endocrine functions as well, disturbances of which have
important clinical repercussions.
In the following we shall discuss three topics illustrating the
recent change of paradigms to explain disturbances in renal
failure related to abnormal renal endocrine function, that is,
biosynthesis of the secosterol hormone 1,25 0H2D3 (in the
following called calcitriol).
The signal triggering secondary hyperparathyroidism in
incipient renal failure
Elevated levels of intact PTH are noted in a considerable
proportion of renal patients with incipient renal failure, that is,
GFR 60 to 80 ml/min [1]. This observation points to early
hyperparathyroidism and raises the issue which signal is respon-
sible for activation of the parathyroid gland. Two decades ago Neil
Bricker proposed the following ingenious hypothesis (Table 1). As
GFR decreases, serum phosphate concentration has a tendency to
increase, at least post-prandially; the ensuing decreased levels of
ionized calcium should trigger the release of PTH and thus
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increase phosphate clearance. The final result would be (near)
normal serum phosphate concentrations at the price of elevated
PTH concentrations. Hyperparathyroidism was thus felt to be a
"trade-off" for the homeostasis of serum phosphate concentration
[2].
This hypothesis has proved very useful in stimulating many
experiments, but it may not fully explain the findings in incipient
renal failure. As shown in Figure 1, the circadian profile of serum
phosphate concentrations under baseline conditions and follow-
ing a phosphate load was absolutely identical in patients with
incipient renal failure and in healthy controls [3]. It may still be
that serum phosphate concentrations are not an adequate reflec-
tion of the concentration of phosphate in some hypothetical
subcellular (renal?) compartment involved in control of renal
1-a-hydroxylase activity, that is, the enzyme responsible for the
generation of calcitriol. Despite various reports to the contrary
[4], when we placed patients with incipient renal failure on
reduced phosphate intake [5] we failed to note a return of
calcitriol concentrations into the normal range.
These observations are difficult to reconcile with a crucial role
of phosphate in the genesis of hyperparathyroidism in incipient
renal failure. It goes without saying that a solid body of experi-
mental and clinical evidence points to an important role of
phosphate in hyperparathyroidism of advanced renal failure.
Moreover, recent in vivo evidence from experimental [6, 71 and
clinical studies is even compatible with a direct stimulating role of
phosphate on the parathyroids unrelated to ionized calcium and
calcitriol. Nevertheless, it appears that an alternative, or at least
complementary, explanation must be sought.
We have reasoned [8] that nephron loss or malfunction in
incipient renal failure diminishes the activity of 1-a-hydroxylase,
allowing the parathyroid to escape from negative feedback control
(Fig. 2). The increase in PTH activity would stimulate renal
1-a-hydroxylase activity and thus return calcitriol levels to the
(near) normal range. As a final result calcitriol levels would be
normal but at the price of elevated PTH concentration. It is quite
obvious that a simple scheme as depicted in Figure 2 neglects a
number of confounding factors which have become apparent
recently: (i) the calcium receptor of the parathyroid that has
recently been cloned [9] and may play a calcitriol-independent
role; the behavior of the receptor during Ca depletion and renal
failure is currently not well established [10]; (ii) furthermore,
recent studies, at least in advanced renal failure, are compatible
with covalent modification and abnormal nuclear uptake of the
vitamin D receptor [11]; and finally, (iii) PTH receptors [12] and
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Table 1. Two paradigms to explain secondary hyperparathyroidism of
incipient renal failure
S GFRPifCa2PTHftCP'11'
final result: normal serum phosphate
elevated PTH [2]
• GFR 4J' 1-a hydroxylase 'IJ' ' PTH 'fl' ' 1,25 0H2D3 'fl'
final result: normal 1,25 0H2D3
elevated PTH [91
actions of PTH on bone [131 appear to be abnormal in renal
failure. Nevertheless, despite such shortcomings, the above sim-
plified scheme would be consistent with the following observa-
tions.
A negative feedback system can be tested dynamically by a
step-change of an input variable. Lucas, Brown and Woodhead
[141 examined plasma calcitriol levels in kidney donors who
underwent unilateral nephrectomy. A consistent decrease of
plasma calcitriol levels was noted. Levels returned to the normal
range (Fig. 3), but at the price of elevated PTH concentrations.
Conversely, when exogenous 1,38 hPTH, that is, the aminotermi-
nal fragment of the human PTH, was infused in patients with
incipient renal failure, stimulation of renal biosynthesis of calcit-
riol, as reflected by the acute increase in calcitriol serum levels,
was diminished in proportion to baseline PTH concentrations. It
was most markedly diminished in those patients with the highest
PTH levels [15]. This observation suggests that in incipient renal
failure 1-a-hydroxylase is stimulated already to such a degree that
it becomes relatively refractory to further stimulation by exoge-
nous PTH.
Finally, a role for calcitriol deficiency is suggested by the
following observation: reversal of parathyroid overactivity in
patients with incipient renal failure following the administration
of calcitriol [16] and prevention of secondary hyperparathyroid-
ism in dogs with experimental uremia following the administration
of calcitriol [17]. We have recently been able to show [181 that in
patients with incipient renal failure and hyperparathyroidism
relatively modest doses of calcitriol, that is, 0.125 tg/day are able
to prevent a further increment of intact PTH in the absence of any
change in serum calcium, urinary calcium or serum phosphate,
thus providing further evidence for the important role of calcitriol
deficiency.
Genesis of parathyroid hyperplasia
In the past it had been assumed that parathyroid hyperplasia
was a regulatory phenomenon. Stimulation of parathyroid leads to
(i) increased mRNA of pre-pro-PTH in individual parathyroid
cells and (ii) recruitment of hormonally active parathyroid cells by
parathyroid cell proliferation (parathyroid hyperplasia) (Fig. 2)
[19]. The genesis of parathyroid hyperplasia is of great importance
since it is poorly reversible; at least its reversal by apoptosis is an
extremely slow process [20]. Experimental studies [21] document
that parathyroid hyperplasia can easily be prevented but is difficult
to reverse [21]. The mechanisms underlying parathyroid hyper-
plasia are therefore of obvious clinical relevance.
One striking observation is the fact that the relative risk of the
dialysis patient to require parathyroidectomy increases dramati-
cally with duration of dialysis [22]. Furthermore, staining of
parathyroid cells for nuclear calcitriol receptors shows inhomog-
enous nuclear uptake of stain, regions with higher staining
actually being juxtaposed to regions with low staining activity. This
observation is compatible with the note that regions with low
receptor expression escape from inhibition of proliferation by
calcitriol receptor [21]. Recently, Fukuda et a! [23] documented
that calcitriol receptor expression was lower in patients with
advanced nodular than diffuse parathyroid hyperplasia.
That parathyroid hyperplasia is not exclusively a regulatory
phenomenon has become apparent from a number of clinical
observations, such as the high rate of local recurrence after
parathydroidectomy [24], the occurrence of locally invasive
growth of parathyroid autotranspiants in forearms [25], the risk
being particularly high in grafts with DNA content outside the
diploid range or in the presence of increased numbers of mitoses
within the gland. All these abnormalities point to abnormal
growth control.
It has recently become obvious that there is a molecular
biological basis to abnormal parathyroid growth. Falchetti et al
[26] reported on clonal allelic loss of genes on chromosome 11q13
coding for putative tumor suppressor genes [26]. Using X-chro-
mosome inactivation analysis with the M27-J3-DNA polymor-
phism, Arnold et a! [27] demonstrated monoclonal growth in at
least 64% of uremic patients with refractory hyperparathyroidism.
The gene(s) responsible for monoclonality has not been identi-
fied. Apparently, somatic mutations confer a growth advantage to
clones of parathyroid cells thus causing monoclonal growth and
nodular parathyroid hyperplasia (although the two phenomena
are not strictly linked). It appears that in the hyperproliferative
environment of the parathyroid gland such mutated cells prolif-
erate in an uncontrolled fashion. This may be similar to the
sequence of events that has been postulated in the genesis of
papillary renal cell tumors of kidneys in end-stage renal failure
[28].
Actions of calcitriol unrelated to calcium homeostasis
In the mammalian organism, calcitriol is crucial for the hor-
monal control of calcemia and calcium balance. It has become
apparent, however, that calcitriol is a phylogenetically ancient
substance that has actions on many non-classical target organs.
Deficiency of calcitriol may therefore be relevant to the under-
standing of some aspects of uremia that are unrelated to calcium
homeostasis [29].
Following observations that cows ingesting a plant, Trisetum
flavescens, develop hypercalcemia from vitamin D intoxication
and are no longer able to produce milk, Zucker, Stark and
Rambeck [30] were able to show UV light-dependent synthesis of
cholecalciferol by Trisetum flavescens. Another plant species,
Solanum malacoxylon, has even been shown to synthesize 1,25
0H2D3 [31]. Calcitriol affects cellular calcium concentration, it
suppresses cell profileration and promotes cell differentiation,
such as rhizogenesis [32]. Are these phylogenetically ancient
actions relevant in humans [33]? Ricketic children frequently die
from infection; more recently, this found an explanation by the
observation that calcitriol plays an important role in macrophage
function and in immune regulation. Furthermore, ricketic chil-
dren exhibit a vitamin D-dependent form of myopathy [34]. It is of
note that painters in Northern countries, such as the Netherlands
and Germany, depicted the Jesus Christ baby with a frog belly (a
sign of ricketic myopathy), a feature which is consistently absent in
illustrations of Italian painters living on the sunlit shores of the
Mediterranean.
More recently, calcitriol receptors in, and calcitriol actions on a
number of non-classical target tissues have been recognized,
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Fig. 2. Schematic representation of the endocrine feedback relationship
between the parathyroid gland and the kidney. Abbreviations are: PTH,
parathyroid hormone; PT, parathyroid cells.
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Fig. 1. Six patients with incipient renal failure
(Ce, 65 mllmin) and 6 healthy control (Cr0 148
mI/mm) were studied between 9 a.m. and 3 p.m.
on the first day without (—) and on the second
day with (———) an oral P load administered at 9
a.m. (1 g P170 kg given as Na-K-phosphate
buffered atpH Z4 and dissolved in 100 ml
water). Note no difference between the
circadian profile in patients with renal failure
and controls [3].
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Fig. 3. Plasma 1,25 0H2D3 concentrations following uninephrectomy in life
donors of renal transplants [14].
improved, for instance, immune functions and glucose-stimulated
insulin secretion.
One of the phylogenetically ancient functions of calcitriol is to
suppress cell proliferation. This has been shown in renal carci-
noma cells [35] and in normal renal cells, that is, compensatory
1 3 5 7
particularly endocrine tissue, skin tissue, muscle tissue (skeletal
muscle, cardiomyocytes and smooth muscle cells), endothelial
cells, hematologic cells and neuronal cells.
Space does not permit an in depth discussion of these findings,
but it is of note that in uremic patients administration of calcitriol
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growth after uninephrectomy [36], mesangial cells [37], and
proximal tubular cell cultures [38]. Since glomerular growth is
apparently a permissive factor which favors the genesis of glomer-
ulosclerosis, the question arises whether such action of calcitriol
can be harnessed to attenuate the development of glomeruloscle-
rosis. This possibility is, indeed, suggested by preliminary studies
which require further confirmation.
It appears then that calcitriol deficiency, and abnormalities of
such phylogenetically ancient actions of calcitriol, may account for
some aspects of uremic syndrome. We agree that there is an
element to teleology in this argumentation but, according to
Beveridge, "teleology is a lady without whom no biologist can live;
and yet he is ashamed to show himself in public with her" [39].
Reprint requests to Prof Dr. Eberhard Ritz, Klinikum der Universitãt
Heidelberg, Sektion Nephrologies, Bergheimer Str. 56a, 69115 Heidelberg,
Germany.
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